期刊
CLINICAL NEUROPHARMACOLOGY
卷 35, 期 2, 页码 77-80出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNF.0b013e31824644e6
关键词
natalizumab; multiple sclerosis; EDSS; annual relapse rate; real-life
资金
- Merck Serono
- Biogen
- Merck Serono
- Bayer Health Care
- Biogen Idec
- Novartis
- Teva Pharmaceuticals
Objectives: Therapy for relapsing-remitting multiple sclerosis with natalizumab (Tysabri; Biogen Idec) has been shown to be effective in the reduction of the clinical relapse rate and disability progression. However, real-life longitudinal data, including years before baseline, are rare. Methods: An observational single-center study was carried out. We analyzed data from 64 consecutive patients with multiple sclerosis. Results: After 1 year of treatment (n = 64), score on the Expanded Disability Status Scale (EDSS) decreased by 0.47 points (P = 0.047) and the annualized relapse rate (ARR) decreased by 82% (P < 0.001). After 2 years (n = 41), EDSS score was still reduced by 0.28 (not significant) and ARR was reduced by 69% (P < 0.001). After 3 years (n = 23), EDSS score was reduced by 0.26 (not significant), and ARR was reduced by 77% (P < 0.001). Reduction of EDSS score and ARR did not depend on baseline ARR (1-2 vs 92) or EDSS score and was not biased by exceptional high disease activity or relapses around baseline. Conclusions: These real-life data reinforce that natalizumab is effective over years, reduces ARR, and stabilizes EDSS score independent of baseline ARR, baseline EDSS score, or baseline treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据